This study highlights the therapeutic potential of targeting the CDK5-FBXO22-PD-L1 pathway in NSCLC treatment, suggesting that CDK5 inhibitors could enhance the efficacy of immunotherapy and DNA-damaging therapies. This evidence concerns the gene CD274 and non-small cell lung carcinoma.